MONTREAL, May 14 /CNW Telbec/ - Haemacure Corporation (TSX : HAE)
announces that it has obtained the consent required from its shareholders to
commence implementing a financing strategy designed to get back into the
clinic for the pivotal Phase II/Phase III clinical trials for its next
generation, all-human fibrin sealant during Q1-2009. The strategy involves the
amendment of the terms and conditions of 62.5 million outstanding Series B
common share purchase warrants issued by Haemacure by way of private placement
in January 2007.
